Press & News Coverage

Browse our press releases and news coverage.

For more information or to request a press pack, contact our Head of PR, Courtney Glymph

View all

In the news

Science Ventures Series: UK start-ups & later-stage fundraising

Guy Levy-Yurista, CEO of Synthace, providing insights on UK start-ups and later-stage fundraising. What are the most important aspects and how do you demonstrate product-market fit?

Seeing double: the rise of digital twins in life sciences

Feb 2022 - Little more than a decade ago, the concept of digital twins in life science research may have sounded more like science fiction than a viable model for research and development (R&D). Read the article to learn about digital twin

Bringing Bioprocess Data Together

February 2022 - Synthace built software that collects data in the cloud in minutes so that anyone can have secure access to it at any time.

Four bioscience predictions for 2022

January 2022 - Cloud computing will dramatically accelerate the rate of biological discovery. Read the article to see the emerging trends in the space.

Biosciences in 2022: Bioscience Reaps Benefits From the Cloud

January 2022 - The article explains how three areas in life sciences have the potential for transform the industry and where we are observing substantial shifts.

Key reaction components affect the kinetics and performance robustness of cell-free protein synthesis reactions

Jan 2022- This paper describes a statistical Design of Experiments analysis of 20 components of a popular cell-free protein synthesis reaction buffer, and identifies factors and factor interactions that impact on protein yield, rate of reaction, lag time and reaction longevity.

IDBS and Synthace Announce Strategic Partnership To Streamline Bioprocess Data Management

Dec 21, 2021- IDBS and Synthace have entered into a strategic partnership to provide IDBS Polar™ users with state-of-the-art data foundations for experimentation in high-throughput process development.

Follow the Money: Cloud R&D, Generative Biology, Robotics

Dec 2, 2021- Synthace has raised $35 million in Series C funding. The investment will fuel commercial and go-to-market growth as Synthace continues to radically reinvent the full value chain of life sciences R&D.

In the news

Science Ventures Series: UK start-ups & later-stage fundraising

May 2022 - Kicking off the series is Guy Levy-Yurista, CEO of Synthace, providing insights on UK start-ups and later-stage fundraising. What are the most important aspects and how do you demonstrate product-market fit?

Seeing double: the rise of digital twins in life sciences

Feb 2022 - Little more than a decade ago, the concept of digital twins in life science research may have sounded more like science fiction than a viable model for research and development (R&D). Read the article to learn about digital twin

Bringing Bioprocess Data Together

February 2022 - Synthace built software that collects data in the cloud in minutes so that anyone can have secure access to it at any time.

Four bioscience predictions for 2022

January 2022 - Cloud computing will dramatically accelerate the rate of biological discovery. Read the article to see the emerging trends in the space.

Biosciences in 2022: Bioscience Reaps Benefits From the Cloud

January 2022 - The article explains how three areas in life sciences have the potential for transform the industry and where we are observing substantial shifts.

Key reaction components affect the kinetics and performance robustness of cell-free protein synthesis reactions

Jan 2022- This paper describes a statistical Design of Experiments analysis of 20 components of a popular cell-free protein synthesis reaction buffer, and identifies factors and factor interactions that impact on protein yield, rate of reaction, lag time and reaction longevity.

IDBS and Synthace Announce Strategic Partnership To Streamline Bioprocess Data Management

Dec 21, 2021- IDBS and Synthace have entered into a strategic partnership to provide IDBS Polar™ users with state-of-the-art data foundations for experimentation in high-throughput process development.

Follow the Money: Cloud R&D, Generative Biology, Robotics

Dec 2, 2021- Synthace has raised $35 million in Series C funding. The investment will fuel commercial and go-to-market growth as Synthace continues to radically reinvent the full value chain of life sciences R&D.

View all

Introducing Synthace, the world’s most powerful software platform for performing biological experiments

​​Intelligent software for the dynamic use of laboratory automation

Sophisticated experiments made simple

🔝